康哲药业宣布,其自主研发的创新药补体因子B抑制剂CMS-D017已获得临床试验批准,适应症为阵发性睡眠性血红蛋白尿症(PNH)。此次获批标志着该药物正式进入临床开发阶段,有望为PNH患者提供新的治疗选择。
康哲药业宣布,其自主研发的创新药补体因子B抑制剂CMS-D017已获得临床试验批准,适应症为阵发性睡眠性血红蛋白尿症(PNH)。此次获批标志着该药物正式进入临床开发阶段,有望为PNH患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.